Combioxin Highlights Results from Successful CAL02-001 First-in-Human Trial Evaluating CAL02 in Severe Pneumonia at ESICM 2018

October 24, 2018
Combioxin SA

Geneva, Switzerland, 24 October 2018 – Combioxin SA, a clinical-stage biotechnology company focused on the development of innovative treatments for severe and resistant infections, announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.

Press Release available here: